Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

Inclusion Criteria:

Patient Inclusion:

- Patient may have M0 or M1 disease

- Confirmed diagnosis of CRPC defined by both Testosterone at castrate levels, as
evidenced by a serum testosterone level ≤ 1.73 nmol/L (50 ng/dL) and Clear progressive
disease, as evidenced by a minimum of two rising PSA levels measured at least 7 days
apart or new clinical or imaging evidence of progressive metastatic disease

- Initiating the first or second line treatment for CRPC: including anti- androgens,
androgen synthesis inhibitors, chemotherapy, immunotherapy or radionuclide therapy.
Previous first line CRPC treatments are limited to: First generation anti-androgens
(bicalutamide, flutamide, or nilutamide) or Sipuleucel-T

- Patients may be enrolled within 90 days from the time of decision to treat or within
90 days of treatment initiation.

- Willing and able to complete periodic patient-reported outcome (PRO) questionnaires,
with or without assistance

- Estimated life expectancy of ≥ 6 months

Caregiver Inclusion:

- Meets the definition of an unpaid relative or friend who helps the patient with his or
her activities of daily living

- Willing and able to complete caregiver-reported outcome questionnaires over the course
of the patient's participation in the study

Exclusion Criteria:

Patient Exclusion:

- Receiving concomitant treatment for other cancer (excluding basal cell carcinoma,
squamous cell carcinoma and treatment for hormone sensitive prostate cancer) within 6
months prior to enrollment.